Dato-DXd + Rilvegostomig for Non-Small Cell Lung Cancer

(TROPION-Lung10 Trial)

Recruiting at 255 trial locations

Overseen By AstraZeneca Clinical Study Information Center

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: AstraZeneca

Disqualifiers: Autoimmune disorders, Severe diseases, Brain metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 3

Duration: Approximately 4 years

675 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests new treatments for individuals with advanced non-small cell lung cancer (NSCLC) that cannot be treated with surgery or certain other therapies. Researchers aim to evaluate the effectiveness and safety of combining two drugs, Datopotamab Deruxtecan (a TROP2-directed antibody-drug conjugate) and Rilvegostomig, compared to the standard treatment, Pembrolizumab. Participants should have non-squamous NSCLC with specific tumor characteristics, such as high PD-L1 expression, which can influence the immune system's response to cancer. The trial seeks individuals who have not received prior systemic therapy for advanced NSCLC and do not have certain genetic mutations that would make other targeted therapies suitable. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Previous studies have shown promising results for datopotamab deruxtecan (Dato-DXd) in patients with advanced non-small cell lung cancer (NSCLC). Most patients tolerated Dato-DXd well, though some experienced manageable side effects. Rilvegostomig, tested alone, was also found to be safe. It targets specific body parts to enhance the immune system's ability to fight cancer cells.

The combination of Dato-DXd with rilvegostomig has shown encouraging results in treating NSCLC, with safety closely monitored. Reports indicate that side effects were manageable and similar to those of other similar treatments. While specific side effects can vary, these treatments were generally well-tolerated in the studies, suggesting they might be safe options for those considering joining a clinical trial. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig because this duo offers a novel approach to treating non-small cell lung cancer (NSCLC). Unlike standard treatments such as chemotherapy and targeted therapies, Dato-DXd is an antibody-drug conjugate that specifically targets cancer cells, potentially reducing damage to healthy cells. Rilvegostomig, a new player in the field, adds another layer of precision by potentially enhancing the immune system's response to cancer. This combination aims to improve effectiveness and reduce side effects compared to existing options.

What evidence suggests that this trial's treatments could be effective for non-small cell lung cancer?

Research has shown that the combination of Datopotamab Deruxtecan (Dato-DXd) and rilvegostomig, administered to participants in one arm of this trial, holds promise for treating non-small cell lung cancer (NSCLC). In a study, 68.2% of patients with advanced cancer experienced significant tumor shrinkage, and 95.5% maintained disease control.

Rilvegostomig alone, tested in a separate arm of this trial, also appears promising. It blocks PD-1 and TIGIT, proteins that allow cancer to evade the immune system. Studies indicate it can provide lasting benefits and is generally safe for patients with PD-L1–positive advanced NSCLC, suggesting it might be effective on its own. ^{6 7 8 9 10}

Who Is on the Research Team?

Suresh S. Ramalingam, MD

Principal Investigator

Emory University, Atlanta, Georgia, United States of America.

Are You a Good Fit for This Trial?

This trial is for adults with advanced non-squamous NSCLC that has high PD-L1 expression (TC ≥ 50%) and no treatable gene changes. Participants should not have had prior therapy for their condition.

Inclusion Criteria

I am fully active or can carry out light work.

My organs and bone marrow are functioning well.

I can provide a tumor sample for testing.

Exclusion Criteria

Active or prior documented autoimmune or inflammatory disorders (with exceptions)

History of active primary immunodeficiency

I have fluid build-up that can't be regularly drained.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Dato-DXd in combination with rilvegostomig, rilvegostomig monotherapy, or pembrolizumab monotherapy as intravenous (IV) infusion every 3 weeks

Approximately 4 years

Every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

Approximately 6 years

What Are the Treatments Tested in This Trial?

Interventions

• Datopotamab Deruxtecan
• Pembrolizumab

Trial Overview The study tests Dato-DXd with Rilvegostomig or just Rilvegostomig against Pembrolizumab alone in first-line treatment. It aims to see which is more effective and safe for this type of lung cancer.

How Is the Trial Designed?

Group I: Arm 2: Rilvegostomig Monotherapy Experimental Treatment 1 Intervention

Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Group II: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig Experimental Treatment 2 Interventions

Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Group III: Arm 3: Pembrolizumab Monotherapy Active Control 1 Intervention

Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials

4,491

Recruited

290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Daiichi Sankyo

Industry Sponsor

Trials

443

Recruited

493,000+

Hiroyuki Okuzawa

Daiichi Sankyo

Chief Executive Officer

Degree in Social Sciences from Hitotsubashi University

Yuki Abe

Daiichi Sankyo

Chief Medical Officer since 2023

MD

Published Research Related to This Trial

In a phase II trial involving 15 patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant treatment with pembrolizumab showed a major pathologic response in 27% of patients, indicating promising antitumor activity before surgery.

The treatment was found to be feasible and safe, with only 33% of patients experiencing moderate adverse events, and no postoperative mortality, suggesting that pembrolizumab does not compromise surgical outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Eichhorn, F., Klotz, LV., Kriegsmann, M., et al.[2022]

In a study of 226 gastric adenocarcinoma patients, the 22C3 and 28-8 pharmDx assays showed strong concordance in measuring programmed death ligand-1 (PD-L1) expression, indicating they may be interchangeable for assessing PD-L1 levels.

The 22C3 assay identified a higher rate of PD-L1 positivity (28%) compared to the 28-8 assay (20%), but both assays correlated with tumor characteristics such as mismatch repair proteins and Epstein-Barr virus status, suggesting their relevance in treatment decisions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. Narita, Y., Sasaki, E., Masuishi, T., et al.[2022]

The TROPION-Lung08 phase III study is investigating the combination of datopotamab deruxtecan (Dato-DXd) and pembrolizumab as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) who have high PD-L1 expression and no actionable genomic alterations, aiming to improve long-term disease control compared to pembrolizumab alone.

Primary endpoints of the study include progression-free survival and overall survival, with secondary endpoints assessing response rates and safety, indicating a comprehensive evaluation of the new treatment's efficacy and safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Levy, BP., Felip, E., Reck, M., et al.[2023]

Pembrolizumab (Keytruda) effectively blocks the PD-1 pathway, enhancing T-cell activity against tumors, which supports its role in promoting tumor regression and immune rejection.

Preclinical studies in cynomolgus monkeys showed that pembrolizumab has a favorable safety profile with no significant toxicological findings, aligning with its demonstrated safety and efficacy in human clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab. Hutchins, B., Starling, GC., McCoy, MA., et al.[2021]

Datopotamab deruxtecan (Dato-DXd) is a promising new treatment for patients with metastatic HR+/HER2- breast cancer, particularly for those who have limited options after endocrine therapy and chemotherapy.

The ongoing phase III TROPION-Breast01 study is comparing the efficacy and safety of Dato-DXd against standard chemotherapy in patients who have already received one or two lines of systemic treatment, aiming to improve outcomes in this challenging patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Bardia, A., Jhaveri, K., Kalinsky, K., et al.[2023]

In a phase II study involving 152 patients with HER2-mutant metastatic non-small-cell lung cancer, trastuzumab deruxtecan (T-DXd) showed a confirmed objective response rate of 49% at 5.4 mg/kg and 56% at 6.4 mg/kg, indicating robust antitumor activity.

The safety profile of T-DXd was generally manageable, with fewer severe adverse events reported in the 5.4 mg/kg group compared to the 6.4 mg/kg group, suggesting that the lower dose may be preferable for patient safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. Goto, K., Goto, Y., Kubo, T., et al.[2023]

In a phase I trial, the TROP2-directed antibody-drug conjugate datopotamab deruxtecan showed promising activity in patients with advanced or metastatic non-small cell lung cancer, with nearly 25% of participants responding to the treatment.

The treatment was associated with manageable side effects, suggesting it could be a safe option for patients with this type of lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

TROP2 ADC Intrigues in NSCLC. [2021]

Datopotamab deruxtecan (Dato-DXd) demonstrated promising antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC), achieving an objective response rate of 26% and a median duration of response of 10.5 months in a study involving 210 patients.

The treatment was generally well-tolerated, with a maximum tolerated dose of 8 mg/kg and a recommended dose of 6 mg/kg, although some patients experienced treatment-emergent adverse events, including nausea and interstitial lung disease, indicating a manageable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. Shimizu, T., Sands, J., Yoh, K., et al.[2023]

A network meta-analysis of five trials showed that PD-1 inhibitors (pembrolizumab and nivolumab) had higher overall response rates (ORR) compared to the PD-L1 inhibitor (atezolizumab), particularly in patients with high PD-L1 expression.

Both pembrolizumab and nivolumab demonstrated superior overall survival (OS) benefits in various patient subgroups, but treatment decisions should also consider individual patient characteristics and safety profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Almutairi, AR., Alkhatib, N., Martin, J., et al.[2019]

In the KEYNOTE-189 study, patients with non-squamous non-small cell lung cancer who received the combination of pembrolizumab, pemetrexed, and platinum had a median progression-free survival (PFS) of 9.3 months, significantly longer than the 6.6 months observed in the placebo group, indicating enhanced efficacy of the treatment.

The objective response rate was also higher in the pembrolizumab group (58.7%) compared to the placebo group (28.9%), while the incidence of severe treatment-emergent adverse events (grade ≥3) was similar across both treatment arms, suggesting a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. Garon, EB., Kim, JS., Govindan, R.[2021]

Pembrolizumab, a PD-1 inhibitor used in cancer treatment, can lead to rare but serious immune-related adverse events, including type 1 diabetes mellitus, occurring in about 0.2% of cases.

A review of 42 cases revealed that patients may develop diabetic ketoacidosis during treatment, highlighting the need for blood glucose monitoring and awareness of this potential side effect among clinicians.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. Clotman, K., Janssens, K., Specenier, P., et al.[2022]

In a phase 1a/b trial involving 26 patients with PD-L1-positive non-small cell lung cancer (NSCLC), the combination of ramucirumab and pembrolizumab showed a manageable safety profile, with 84.6% experiencing treatment-related adverse events, primarily hypertension.

The treatment demonstrated promising efficacy, with an objective response rate of 42.3%, and particularly strong results in patients with high PD-L1 expression (TPS ≥ 50%), who had a median progression-free survival that was not reached.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Herbst, RS., Arkenau, HT., Bendell, J., et al.[2023]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12034271/

Therapeutic Potential of Datopotamab Deruxtecan in the ... If approved, datopotamab deruxtecan will be the first TROP2-directed antibody–drug conjugate for non-small cell lung cancer. Keywords ...

2. daiichisankyo.us daiichisankyo.us/press-releases/-/article/datroway%25C2%25AE-continues-to-show-promising-tumor-responses-as-part-of-combination-regimens-in-patients-with-early-and-advanced-non-small-cell-lung-cancer

DATROWAY® Continues to Show Promising Tumor ... “Patients with non-small cell lung cancer have limited treatment options and often experience disease progression due to the aggressive nature ...

3. datasourcebydaiichisankyo.com datasourcebydaiichisankyo.com/documents/d/datahub/tropion-lung10_tip_elcc-2025_24march2025_for-upload

TROPION-Lung10: Phase 3 study of datopotamab ... Rilvegostomig has shown preliminary efficacy, with an ORR of 62%, and an acceptable safety profile in patients with advanced/metastatic NSCLC ...

4. daiichisankyo.us daiichisankyo.us/press-releases/-/article/datroway-plus-rilvegostomig-showed-promising-tumor-responses-in-patients-with-metastatic-urothelial-cancer-in-tropion-pantumor03-phase-2-trial

DATROWAY Plus Rilvegostomig Showed Promising Tumor ... Download the PDF version of Article. October 17, 2025. A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was ...

5. asco.org asco.org/abstracts-presentations/ABSTRACT482236

Results from TROPION-Lung04 (cohort 5). Dato-DXd + rilvegostomig had encouraging activity as 1L treatment for pts with a/mNSCLC without AGAs, with responses seen in both histologies and across all PD ...

6. ascopubs.org ascopubs.org/doi/10.1200/JCO-24-01544

Datopotamab Deruxtecan Versus Docetaxel for Previously ... Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology.

7. clinicaltrials.gov clinicaltrials.gov/study/NCT06564844

Study Details | NCT06564844 | A Phase III, Randomised ... This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig ...

8. ascopubs.org ascopubs.org/doi/abs/10.1200/JCO-24-01349

Datopotamab Deruxtecan in Advanced or Metastatic Non– ... Encouraging and durable antitumor activity was observed with Dato-DXd in this heavily pretreated advanced/metastatic NSCLC population with actionable genomic ...

9. astrazenecaclinicaltrials.com astrazenecaclinicaltrials.com/study/D926TC00001

A Phase III, Randomised Study of Adjuvant Dato-DXd in ... This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig ...

10. asco.org asco.org/abstracts-presentations/ABSTRACT332873

A randomized, phase 3 study of datopotamab deruxtecan ... This phase 3 study (NCT04656652) will compare the efficacy of Dato-DXd with that of docetaxel as 2/3L therapy in patients with advanced/metastatic NSCLC.